| Formulary Chapter 6: Endocrine system - Full Chapter
|
| 06.01.02.03 |
Other antidiabetic drugs |
|
|
| 06.01.02.03 |
DPP-4 inhibitors |
|
|
| 06.01.02.03 |
Alpha glucosidase inhibitors |
|
|
| 06.01.02.03 |
GLP-1 mimetics |
|
|
| 06.01.02.03 |
DPP4 inhibitors (gliptins) |
|
|
| 06.01.02.03 |
SGLT2 inhibitors |
|
|
| 06.01.02.03 |
GLP1 agonists |
|
|
| 06.01.02.03 |
SGL2 inhibitors |
|
|
Canagliflozin
|
Formulary
|
For treating Type 2 diabetes in line with NICE, and chronic kidney disease.
Do not use SGLT2-inhibitors in patients with T1DM, regardless of CKD and/or heart failure status due to risk of DKA (diabetic ketoacidosis)
|
| 06.01.02.03 |
Thiazolidinediones |
|
|
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
for treating Type 2 diabetes and chronic kidney disease in line with NICE 
Treatment of all grades of symptomatic heart failure 
